Related Experiment Video

Updated: May 30, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Between Scylla and Charibdis: eIF2α kinases as targets for cancer chemotherapy

Marta Moreno-Torres1, José R Murguía

  • 1Department of Stress Biology, Instituto de Biología Molecular y Celular de Plantas (UPV-CSIC), Valencia, Spain.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|July 22, 2011
PubMed

Insights

Eukaryotic initiation factor 2 alpha (eIF2α) kinases help cells adapt to low nutrients. These kinases also play roles in cancer, affecting cell cycle, genome stability, and response to chemotherapy.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • eIF2α kinases regulate translation initiation in response to nutrient availability.
  • These kinases are crucial for cellular adaptation to nutrient scarcity.
  • Emerging roles in tumor biology highlight their significance in cancer progression.

Purpose of the Study:

  • To explore the multifaceted roles of eIF2α kinases in cancer.
  • To understand how these kinases influence cancer cell adaptation to stress.
  • To investigate the impact of eIF2α kinases on chemotherapy efficacy.

Main Methods:

  • Literature review of recent evidence on eIF2α kinases in cancer.
  • Analysis of molecular mechanisms underlying kinase function in tumor cells.
  • Examination of kinase modulation of anti-cancer drug activity.

Main Results:

  • eIF2α kinases regulate cell cycle, genome stability, apoptosis, and survival under stress.
  • Active eIF2α kinases influence cancer cell response to nutrient deprivation and hypoxia.
  • These kinases modulate the efficacy of antineoplastic drugs, impacting cytotoxicity and chemoresistance.

Conclusions:

  • eIF2α kinases are key regulators of cancer cell adaptation to nutrient stress.
  • Understanding their molecular roles offers insights into tumor cell survival mechanisms.
  • Targeting eIF2α kinases may enhance cancer chemotherapy effectiveness.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...